---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-004155"
form_type: "8-K"
ticker: "AYTU"
cik: "0001385818"
company_name: "AYTU BIOPHARMA, INC"
filed_at: "2024-02-14T23:59:59+00:00"
generated_at: "2026-06-06T02:10:48.149508+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Aytu BioPharma reports Q2 fiscal 2024 operating income of $2.4M, first positive; ADHD revenue up 49%

## Summary
- Consolidated net revenue $22.9M, down 13% YoY due to planned wind-down of Consumer Health Segment.
- ADHD Portfolio revenue jumped 49% to $16.6M; Rx Segment gross margin improved to 78% from 72%.
- Operating income $2.4M vs. operating loss of $6.9M a year ago; net loss narrowed to $0.2M from $6.7M.
- Adjusted EBITDA $5.1M (up 599% YoY); cash $19.5M at Dec 31, 2023.
- Company winding down Consumer Health Segment to focus on Rx Segment; expects neutral segment EBITDA for FY2024.

## SEC filing metadata
- accession: 0001437749-24-004155
- form_type: 8-K
- ticker: AYTU
- cik: 0001385818
- company_name: AYTU BIOPHARMA, INC
- filed_at: 2024-02-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1385818/000143774924004155/0001437749-24-004155-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1385818/000143774924004155/aytu20240109_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-004155
- JSON: https://secwatch.observer/filing/0001437749-24-004155.json
- Plain text: https://secwatch.observer/filing/0001437749-24-004155.txt

## Key facts
- Earnings Releases
  AYTU BIOPHARMA, INC reported fiscal 2024 second quarter results: revenue $22.9 million, net income $0.2 million, or $0.04 per share, EPS $0.04 per share.
  - Period: fiscal 2024 second quarter
  - Revenue: $22.9 million
  - Net income: $0.2 million, or $0.04 per share
  - EPS: $0.04 per share
  - Result: reported results
  source text: on commercializing novel therapeutics, today announced financial and operational results for the fiscal 2024 second quarter. ​ Q2 2024 Highlights ● Consolidated net revenue was $22.9 million, compared to $26.3 million in the prior year period. The decrease is primarily due to the planned wind down of the Company's Consumer Health Segment. ● ADHD Portfolio (Adzenys
  evidence_url: https://www.sec.gov/Archives/edgar/data/1385818/000143774924004155/0001437749-24-004155-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.